<DOC>
	<DOC>NCT00556257</DOC>
	<brief_summary>A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.</brief_summary>
	<brief_title>Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Recipient of first time kidney transplant Between the ages of 18 and 70 years, inclusive Recipient of any nonkidney transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Immunosuppression, JAK3 inhibitor, kidney transplantation</keyword>
</DOC>